ERBB2 and cancer: Besides, KATHERINE,14 CREATE-X,15 monarchE,16 and OlympiA17,18 trials have suggested the perspective of postoperative treatment for NACT patients who had residual cancer burden with HER2+, TNBC, HR+/HER2-, and germline BRCA1/2 mutation diseases, respectively, leading to improved survival outcomes.19